CN111936143A - 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 - Google Patents

用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 Download PDF

Info

Publication number
CN111936143A
CN111936143A CN201980024687.3A CN201980024687A CN111936143A CN 111936143 A CN111936143 A CN 111936143A CN 201980024687 A CN201980024687 A CN 201980024687A CN 111936143 A CN111936143 A CN 111936143A
Authority
CN
China
Prior art keywords
cancer
indol
inhibitor
methyl
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980024687.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·赫格伯格
S·雷恩马克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novija Research
Original Assignee
Novija Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novija Research filed Critical Novija Research
Publication of CN111936143A publication Critical patent/CN111936143A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980024687.3A 2018-04-05 2019-04-04 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品 Pending CN111936143A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1850380 2018-04-05
SE1850380-5 2018-04-05
PCT/SE2019/050312 WO2019194738A1 (en) 2018-04-05 2019-04-04 Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
CN111936143A true CN111936143A (zh) 2020-11-13

Family

ID=68101552

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980024687.3A Pending CN111936143A (zh) 2018-04-05 2019-04-04 用于治疗癌症的微管蛋白聚合抑制剂和聚(adp-核糖)聚合酶(parp)抑制剂的新型联用药品

Country Status (6)

Country Link
US (1) US11590130B2 (https=)
EP (1) EP3773592B1 (https=)
JP (1) JP7372253B2 (https=)
CN (1) CN111936143A (https=)
CA (1) CA3095709A1 (https=)
WO (1) WO2019194738A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229294B2 (en) 2015-03-06 2021-11-04 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
KR20180105685A (ko) 2016-02-08 2018-09-28 비욘드스프링 파마수티컬스, 인코포레이티드. 투카레솔 또는 이의 유사체를 함유하는 조성물
JP7025416B2 (ja) 2016-06-06 2022-02-24 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症を低減させるための組成物および方法
WO2018129381A1 (en) 2017-01-06 2018-07-12 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
JP2023524530A (ja) * 2020-05-04 2023-06-12 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN121127241A (zh) * 2023-03-10 2025-12-12 万春药业公司 肿瘤联合治疗及使用方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151423A1 (en) * 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012127032A1 (en) * 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
WO2017013593A1 (en) * 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
WO2017083979A1 (en) * 2015-11-20 2017-05-26 Lee Hoyun Quinolone chalcone compounds and uses thereof
US20170209594A1 (en) * 2015-06-25 2017-07-27 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1976515A2 (en) 2006-01-17 2008-10-08 Abbott Laboratories Combination therapy with parp inhibitors
US20100249112A1 (en) 2007-05-25 2010-09-30 Astrazeneca R&D Combination of chk and parp inhibitors for the treatment of cancers
EP2217244A4 (en) 2007-11-12 2011-08-31 Bipar Sciences Inc TREATMENT OF NUTRITIONAL CANCER AND EGG CANCER WITH A PARP INHIBITOR ALONE OR IN COMBINATION WITH ANTITUMOROUS MEDICINES
RU2010128107A (ru) 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
CN101981013B (zh) 2008-03-27 2013-05-29 詹森药业有限公司 作为parp和微管蛋白聚合抑制剂的四氢菲啶酮和四氢环戊二烯并喹啉酮
ES2367760T3 (es) 2008-03-27 2011-11-08 Janssen Pharmaceutica, N.V. Derivados de quinazolinona como inhibidores de la polimerización de la tubulina.
CN102307475A (zh) 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
EP2459561A1 (en) 2009-07-30 2012-06-06 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
TWI577693B (zh) 2011-05-31 2017-04-11 江蘇康緣藥業股份有限公司 聚（ａｄｐ-核糖）聚合酶之三環抑制劑
US9132120B1 (en) 2012-04-02 2015-09-15 Stc.Unm Targeting abnormal DNA repair in therapy-resistant breast and pancreatic cancers
JP6615746B2 (ja) 2013-04-09 2019-12-04 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 腫瘍選択的併用療法
WO2017223516A1 (en) 2016-06-24 2017-12-28 The Regents Of The University Of California Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011151423A1 (en) * 2010-06-04 2011-12-08 Exonhit S.A. Substituted isoquinolines and their use as tubulin polymerization inhibitors
WO2012127032A1 (en) * 2011-03-24 2012-09-27 Chemilia Ab Novel pyrimidine derivatives
US20170209594A1 (en) * 2015-06-25 2017-07-27 Immunomedics, Inc. Synergistic effect of anti-trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or parp inhibitors
WO2017013593A1 (en) * 2015-07-22 2017-01-26 Lupin Limited Isoquinolinone derivatives as parp inhibitors
WO2017083979A1 (en) * 2015-11-20 2017-05-26 Lee Hoyun Quinolone chalcone compounds and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZIGAO YUAN 等: ""PARP inhibitors as antitumor agents: a patent update (2013-2015)"", 《EXPERT OPIN THER PAT》, 27 March 2017 (2017-03-27), pages 1 - 46 *

Also Published As

Publication number Publication date
CA3095709A1 (en) 2019-10-10
US20210052583A1 (en) 2021-02-25
EP3773592A4 (en) 2022-02-23
JP7372253B2 (ja) 2023-10-31
WO2019194738A1 (en) 2019-10-10
EP3773592A1 (en) 2021-02-17
JP2021519262A (ja) 2021-08-10
EP3773592B1 (en) 2025-09-10
US11590130B2 (en) 2023-02-28

Similar Documents

Publication Publication Date Title
JP7372253B2 (ja) 癌の治療における使用のためのチューブリン重合阻害剤とポリ（ａｄｐ－リボース）ポリメラーゼ（ｐａｒｐ）阻害剤との新規組合せ
He et al. PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Neckers et al. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics–an update
US11452725B2 (en) Chiral diaryl macrocycles and uses thereof
Huang et al. Novel hybrid molecule overcomes the limited response of solid tumours to HDAC inhibitors via suppressing JAK1-STAT3-BCL2 signalling
CN115385938A (zh) 苯并嘧啶类化合物、其制备方法及其在医药上的应用
US11666574B2 (en) Combination therapy involving diaryl macrocyclic compounds
BR112017017009B1 (pt) Composição farmacêutica
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
CN110573166B (zh) 用于癌症治疗的吉西他滨衍生物
JPWO2012111790A1 (ja) 化学療法剤の抗腫瘍活性増強剤
CN106132412A (zh) 治疗癌症的新方法
CN101332301A (zh) 一种抗肿瘤组合物及其应用
US12110300B2 (en) Liquid pharmaceutical composition of gold
Li et al. Dual–target platinum (IV) complexes reverse cisplatin resistance in triple negative breast via inhibiting poly (ADP–ribose) polymerase (PARP–1) and enhancing DNA damage
KR20250007465A (ko) Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
JP2024511354A5 (https=)
Abe et al. 356 characterization of TAS-117, a novel, highly potent and selective inhibitor of AKT
US12036215B2 (en) Antitumor agent and method for tumor therapy
Teran Efficacy and Mechanism of Action of a Novel Class of Antic-Cancer Drugs
Sandhu et al. 352 Final Results of the First in Man Trial of MK4827, a Poly (ADP-ribose) Polymerase (PARP) Inhibitor with Antitumor Activity in BRCA Carriers and Sporadic Cancer Patients
JP2014091711A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性白金錯体との組み合わせ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination